Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Date:6/13/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) support the American Diabetes Association (ADA) call for an independent review of the safety data of incretin-based therapies. At BIPI and Lilly, patient safety is our top priority, and we support ongoing efforts to further understand whether diabetes or certain diabetes treatments may affect the risk of pancreatitis and pancreatic cancer.

We welcome future discussion with the ADA to determine how best we can support this initiative and to provide a valuable contribution.

BIPI and Lilly also welcome the discussions taking place this week at the National Institute of Diabetes and Digestive and Kidney Diseases–National Cancer Institute (NIDDK-NCI) Pancreatitis, Diabetes and Pancreatic Cancer Workshop. The workshop was convened, in part, to examine the latest data on whether there is a potential risk of pancreatitis and pancreatic cancer in people with type 2 diabetes as well as those treated with drugs classified as incretin-based therapies.

About Diabetes
Approximately 25.8 million Americans1 and an estimated 371 million people worldwide2 have type 1 or type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.1 Diabetes is a chronic condition that occurs when the body does not properly either produce or use the hormone insulin.3 Diabetes was estimated to cost the U.S. $245 billion in 2012.4

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three compounds representing several of the largest
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
2. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
3. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
5. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
6. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
7. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
8. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
9. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
10. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
11. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... BEIJING , Aug. 4, 2015 Concord Medical ... a leading specialty hospital management solution provider and operator of ... China , today announced it will release ... the market closes on August 17, 2015. Management ... following day, at 8:00 a.m. EDT on August 18, 2015 ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, today ... will present live at VirtualInvestorConferences.com on August 6, ... TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... online event where investors are invited to ask ...
Breaking Medicine Technology:Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3
... , May 10 Ferring Pharmaceuticals ... Women,s Health product portfolio with the acquisition of ... acid), a first-in-class, non-hormonal therapy indicated specifically for ... (HMB).  The company will initially market LYSTEDA in ...
... 10 Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), today announced the ... Mr. Macaluso replaces Dr. David Bar-Or, who remains the Chief Scientific Officer and ... Bar-Or have served on Ampio,s Board since the date of its acquisition of ... , , ...
Cached Medicine Technology:Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 2Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 3Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 4Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 5Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer 2
(Date:8/4/2015)... ... 04, 2015 , ... assistPoint Partners, LLC is proud ... patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, Patients ... level, cloud-based application and workflow solution. This provides cancer center patient advocates, financial ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces ... to fit, for example, on hard hats that have a flip-up face shield. The ... allows users to work without having to remove their headlamp when raising or lowering ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Worldwide Power Products is expanding its reach in Texas. Effective July 1st of ... Systems North Texas generator division. With the North Texas acquisition, Worldwide Power ...
(Date:8/4/2015)... , ... August 04, 2015 , ... One of the ... to discuss his new book, The Pain Antidote , which provides strategies for ... Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction with ...
Breaking Medicine News(10 mins):Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... hospitals , , MONDAY, Dec. 17 (HealthDay News) -- A ... and anxiety that often follows major surgery, new research ... was equivalent to a [dose] of morphine, which was ... Hinshaw, professor of surgery and a member of the ...
... NEW MARTINSVILLE, W.Va., Dec. 17 In ... become tomorrow,s environmental,stewards, Bayer Corporation and the ... (UNEP RONA) today announced a new World,Environment ... Competition in Bayer MaterialScience New Martinsville partner,schools., ...
... OWINGS MILLS, Md., Dec. 17 Medifast, Inc.,(NYSE: ... has received approval to sell,Medifast Weight Control Centers ... available in 43 states. Medifast recently,received approval to ... Rhode Island and Virginia., "The Medifast Weight ...
... season is a,great opportunity to relax, spend time with family, ... the next 12 months. These top resolutions,offered by the American ... healthy new you in 2008., "Creating and sticking to ... you can give yourself this holiday season," said AMA,President, Ron ...
... a high volume of corrective surgeries show higher survival ... -- Babies with congenital heart defects are more likely ... the most experience in treating such cases, U.S. researchers ... figures from the 2003 Kids, Inpatient Database, which is ...
... Murtha, Chairman of the House Appropriations Subcommittee on Defense, this ... veterans blinded by war and for research to restore their ... gives the Man of Vision Award to an individual who ... of the challenges of vision loss. Among previous awardees have ...
Cached Medicine News:Health News:Massage Eases Pain, Anxiety After Surgery 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 3Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 4Health News:Medifast, Inc. Receives Approval to Sell Medifast Weight Control Centers Franchises in Seven Additional States 2Health News:AMA: Resolutions for a Healthy New You in the New Year 2Health News:Babies With Heart Defects Do Best at Hospitals With Most Experience 2Health News:Champion of blinded soldiers, Congressman Murtha, is Man of Vision 2
... The Perc NCircle® is designed to ... nephrolithotomy (PCNL). The Perc NCircle combines traditional ... NCircle nitinol tipless basket technology. The ... NCircle basket allows the surgeon to remove ...
... drainage from the ureteropelvic junction to ... packages. Intended for one-time use. CAUTION: ... Sof-Flex® stents must not remain indwelling ... stents must not remain indwelling more ...
... ACMI Classic Double Pigtail Ureteral ... pigtail design that maximizes migration. They ... added versatility and cost savings. ... Kit contains one Classic Double PigTail ...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection....
Medicine Products: